9IB Stock Overview
A clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Infant Bacterial Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.36 |
| 52 Week High | SEK 9.10 |
| 52 Week Low | SEK 2.75 |
| Beta | 1.04 |
| 11 Month Change | 7.69% |
| 3 Month Change | n/a |
| 1 Year Change | -55.91% |
| 33 Year Change | n/a |
| 5 Year Change | -72.46% |
| Change since IPO | -67.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9IB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.7% | -1.2% | -0.02% |
| 1Y | -55.9% | -20.1% | 8.2% |
Return vs Industry: 9IB underperformed the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: 9IB underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 9IB volatility | |
|---|---|
| 9IB Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 9IB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 9IB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 10 | Staffan Stromberg | www.ibtherapeutics.com |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
Infant Bacterial Therapeutics AB (publ) Fundamentals Summary
| 9IB fundamental statistics | |
|---|---|
| Market cap | €44.75m |
| Earnings (TTM) | -€12.52m |
| Revenue (TTM) | €434.79 |
Over9,999x
P/S Ratio-3.6x
P/E RatioIs 9IB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9IB income statement (TTM) | |
|---|---|
| Revenue | SEK 5.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 5.00k |
| Other Expenses | SEK 144.04m |
| Earnings | -SEK 144.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -10.69 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,880,640.00% |
| Debt/Equity Ratio | 0% |
How did 9IB perform over the long term?
See historical performance and comparison